PT  - JOURNAL ARTICLE
AU  - Stead, David
AU  - Adeniyi, Oladele Vincent
AU  - Singata-Madliki, Mandisa
AU  - Abrahams, Shareef
AU  - Batting, Joanne
AU  - Jelliman, Eloise
AU  - Parrish, Andrew
TI  - Cumulative incidence of SARS-CoV-2 and associated risk factors among healthcare workers in the Eastern Cape, South Africa
AID  - 10.1101/2021.11.08.21265966
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.08.21265966
4099  - http://medrxiv.org/content/early/2021/11/09/2021.11.08.21265966.short
4100  - http://medrxiv.org/content/early/2021/11/09/2021.11.08.21265966.full
AB  - Objectives This study assesses the cumulative incidence of SARS-CoV-2 infection among healthcare workers (HCWs) during South Africa’s first wave and examines the associated demographic, health-related, and occupational risk factors for infection.Methods Multi-stage cluster sampling was used in a cross-sectional study to recruit 1,309 HCWs from two academic hospitals in the Eastern Cape, South Africa over six weeks in November and December 2020. Prior test results for SARS-CoV-2 polymerase chain reaction (PCR) and participants’ characteristics were recorded while a blood sample was drawn for detection of IgG antibodies against SARS-CoV-2 nucleocapsid protein. The primary outcome measure was the SARS-CoV-2 cumulative incidence rate, defined as the combined total of positive results for either PCR or IgG antibodies, divided by the total sample. The secondary outcome was significant risk factors associated with infection.Results Of the total participants included in the analysis (N=1295), the majority were female (81.5%), of black race (78.7%) and nurses (44.8%). A total of 390 (30.1%) HCWs had a positive SARS-CoV-2 PCR result and SARS-CoV-2 antibodies were detected in 488 (37.7%), yielding a cumulative incidence of 47.2% (n = 611). In the adjusted logistic regression model, being overweight (Adjusted odds ratio (AOR) = 2.15, 95% CI 1.44-3.20), obese (AOR = 1.37, 95% CI 1.02-1.85) and living with HIV (AOR = 1.78, 95% CI 1.38-were independently associated with SARS-CoV-2 infection. There was no significant difference in infection rates between high, medium and low COVID-19 exposure working environments.Conclusions The high SARS-CoV-2 cumulative incidence in the cohort was surprising this early in the epidemic and probably related to exposure both in and outside the hospitals. To mitigate the impact of SARS-CoV-2 among HCWs, infection prevention and control (IPC) strategies should target community transmission in addition to screening for HIV and metabolic conditions.Strengths and limitations of this studyThis is a large representative sample of the total workforce of the two hospitals, with a good spectrum of staff category.Combining the historical SARS-CoV-2 PCR results with the Nucleocapsid IgG enabled capturing of some of the asymptomatic and missed SARS-CoV-2 infections.This is one of the first studies to look at SARS-CoV-2 infection risk factors in a high exposure environment in Africa.A limitation is that HIV ELISA and CD4 counts were not tested, but relied on self-report, which may likely underestimate the burden of HIV in the cohort.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.mdpi.com/949364 Funding StatementThis study was funded by the South African Medicine Research Council (SAMRC), and from the personal research funds of 2 of the authors held at Walter Sisulu University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics committee of Walter Sisulu University gave ethical approval for this work. (Reference: 087/2020), The Ethics committee of Cecilia Makiwane and Frere hospitals gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors